He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell...

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for...

Kathryn Chapman has held many roles in town and is an expert on everything Cambridge's life sciences ecosystem has to offer.

Executive director Cathy Tralau-Stewart describes how Milner fosters partnerships.

He will be presenting final data from a 21 patient NHL cohort at the 2024 ASCO Annual Meeting in June.

OSE Partner Claire Brown describes the important role that OSE plays in the helping to turn ideas into companies at Oxford.

Alek Safarian shares his opinions on the current funding environment for biotech, and introduces us to his firm and its investment...

He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over...

He describes how Cloverleaf believes it is different from other tRNA companies and how it has already at the earliest stages benefitted...

McKinsey Boston life science specialists give their take on the goals of the summit and the current state of the sector.

He talks about GV's history in healthcare and lists some investments made in the nearly five years he has been there.

Kendalle Burlin O'Connell describes the goals of the Align Summit and the work MassBio is doing.

He discusses Intra-Cellular, Axsome, Adaptimmune, EyePoint, Insmed, Immunocore, Immatics, and Terns.

Eddie Eltoukhy explains the unique role that seed investors have in helping entrepreneurs succeed, he lists some areas of science of...

He discusses Vertex's acquisition of Alpine Immune Science, Bloomberg's reporting on Janux, and more.

Dr. Yu describes how TCGX's structure and nimbleness has led to investments in number companies that have been acquired over the last year.

Dr. Bertozzi and Dr. Hsiao describe how Acepodia is leveraging biorthogonal chemistry to conjugate antibodies to allogeneic γδ2 T cells.

Thomas Shrader shares his thoughts on biotech and comments on companies he covers.

Andy Hsieh gives his take on the radiopharmaceutical space, Viking’s obesity data, Pyxis Oncology, Cardiff Oncology, Fibrogen.

Evan Seigerman breaks down which companies and technologies are at the forefront of the the GLP space.